PL365133A1 - Krystaliczny środek terapeutyczny - Google Patents

Krystaliczny środek terapeutyczny

Info

Publication number
PL365133A1
PL365133A1 PL01365133A PL36513301A PL365133A1 PL 365133 A1 PL365133 A1 PL 365133A1 PL 01365133 A PL01365133 A PL 01365133A PL 36513301 A PL36513301 A PL 36513301A PL 365133 A1 PL365133 A1 PL 365133A1
Authority
PL
Poland
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
agent
therapeutic
Prior art date
Application number
PL01365133A
Other languages
English (en)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL365133A1 publication Critical patent/PL365133A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PL01365133A 2000-07-28 2001-07-18 Krystaliczny środek terapeutyczny PL365133A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
PL365133A1 true PL365133A1 (pl) 2004-12-27

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365133A PL365133A1 (pl) 2000-07-28 2001-07-18 Krystaliczny środek terapeutyczny

Country Status (46)

Country Link
EP (1) EP1305314B1 (pl)
JP (1) JP2004505087A (pl)
KR (1) KR100457937B1 (pl)
CN (1) CN1207297C (pl)
AP (1) AP1400A (pl)
AR (1) AR032628A1 (pl)
AT (1) ATE286901T1 (pl)
AU (2) AU7269001A (pl)
BG (1) BG107266A (pl)
BR (1) BR0112734A (pl)
CA (1) CA2417264C (pl)
CZ (1) CZ2003126A3 (pl)
DE (1) DE60108398T2 (pl)
DO (1) DOP2001000217A (pl)
DZ (1) DZ3364A1 (pl)
EA (1) EA004681B1 (pl)
EC (1) ECSP034454A (pl)
EE (1) EE200300045A (pl)
ES (1) ES2231521T3 (pl)
GE (1) GEP20053494B (pl)
HK (1) HK1055954A1 (pl)
HR (1) HRP20030061A2 (pl)
HU (1) HUP0302982A3 (pl)
IL (1) IL153226A0 (pl)
IN (1) IN2002MU01649A (pl)
IS (1) IS6626A (pl)
MA (1) MA26931A1 (pl)
MX (1) MX233602B (pl)
MY (1) MY117831A (pl)
NO (1) NO324220B1 (pl)
NZ (1) NZ523226A (pl)
OA (1) OA12337A (pl)
PA (1) PA8523501A1 (pl)
PE (1) PE20020277A1 (pl)
PH (1) PH12001001922B1 (pl)
PL (1) PL365133A1 (pl)
PT (1) PT1305314E (pl)
SK (1) SK572003A3 (pl)
SV (1) SV2001000570A (pl)
TN (1) TNSN01112A1 (pl)
TW (1) TWI285643B (pl)
UA (1) UA72631C2 (pl)
UY (1) UY26854A1 (pl)
WO (1) WO2002010171A1 (pl)
YU (1) YU4703A (pl)
ZA (1) ZA200301457B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1371647E (pt) * 1998-04-20 2005-10-31 Pfizer Derivados do acido piridina-3-carboxilico e sua utilizacao como intermediarios
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AR032628A1 (es) 2003-11-19
ATE286901T1 (de) 2005-01-15
EP1305314A1 (en) 2003-05-02
EE200300045A (et) 2004-12-15
EA004681B1 (ru) 2004-06-24
JP2004505087A (ja) 2004-02-19
ZA200301457B (en) 2004-04-28
WO2002010171A1 (en) 2002-02-07
IS6626A (is) 2002-11-18
TNSN01112A1 (fr) 2005-11-10
EA200300079A1 (ru) 2003-06-26
EP1305314B1 (en) 2005-01-12
HUP0302982A2 (hu) 2003-12-29
DE60108398T2 (de) 2005-12-22
ES2231521T3 (es) 2005-05-16
OA12337A (en) 2006-05-15
DOP2001000217A (es) 2002-10-30
DZ3364A1 (fr) 2002-02-07
DE60108398D1 (de) 2005-02-17
PH12001001922B1 (en) 2006-11-21
SK572003A3 (en) 2004-05-04
BR0112734A (pt) 2004-08-10
CN1444585A (zh) 2003-09-24
MX233602B (es) 2006-01-10
IL153226A0 (en) 2003-07-06
MA26931A1 (fr) 2004-12-20
UA72631C2 (uk) 2005-03-15
CN1207297C (zh) 2005-06-22
NO324220B1 (no) 2007-09-10
PE20020277A1 (es) 2002-05-11
HK1055954A1 (en) 2004-01-30
NO20030416D0 (no) 2003-01-27
KR100457937B1 (ko) 2004-11-20
CA2417264A1 (en) 2002-02-07
PA8523501A1 (es) 2002-10-24
UY26854A1 (es) 2002-02-28
CZ2003126A3 (cs) 2004-02-18
AP1400A (en) 2005-04-28
BG107266A (bg) 2003-07-31
ECSP034454A (es) 2003-03-10
AU2001272690B2 (en) 2005-12-08
CA2417264C (en) 2007-06-12
TWI285643B (en) 2007-08-21
NZ523226A (en) 2003-07-25
YU4703A (sh) 2006-01-16
AP2001002234A0 (en) 2001-09-30
SV2001000570A (es) 2002-09-03
KR20030016430A (ko) 2003-02-26
AU7269001A (en) 2002-02-13
HUP0302982A3 (en) 2005-01-28
GEP20053494B (en) 2005-04-25
IN2002MU01649A (pl) 2004-12-11
HRP20030061A2 (en) 2003-04-30
PT1305314E (pt) 2005-04-29
MY117831A (en) 2004-08-30
NO20030416L (no) 2003-02-05
MXPA03000856A (es) 2003-06-06

Similar Documents

Publication Publication Date Title
GB0023983D0 (en) Therapeutic compounds
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
EP1296698A4 (en) THERAPEUTIC COMPOUNDS
GB0012671D0 (en) Therapeutic agents
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
GB0005789D0 (en) Therapeutic agents
GB0007907D0 (en) Therapeutic agents
GB0012214D0 (en) Therapeutic agents
GB0008696D0 (en) Therapeutic agents
GB0028583D0 (en) Therapeutic compounds
GB0000564D0 (en) Therapeutic agents
GB0007376D0 (en) Therapeutic agents
GB0030067D0 (en) Therapeutic agent
AU7269001A (en) Crystalline therapeutic agent
GB0013105D0 (en) Therapeutic compounds
SI1305314T1 (en) Crystalline therapeutic agent
GB0106464D0 (en) Crystalline therapeutic agent
GB0017049D0 (en) Therapeutic agent
GB0022347D0 (en) Therapeutic compounds
GB0003767D0 (en) Therapeutic compounds
GB0023985D0 (en) Therapeutic compounds
GB0023984D0 (en) Therapeutic compounds
GB0023982D0 (en) Therapeutic Compounds

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)